Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (171-180 of 317) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialEmanuel Bührer, Michal Kicinski, Mario Mandala, et al.
European Urology|June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Melanoma Research|January 3, 2020
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)Elisa A Rozeman, Warner Prevoo, Mark A J Meier, et al.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cardiovascular and Interventional Radiology|January 9, 2023
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin TrialT M L Tong, M C Burgmans, F M Speetjens, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Pageof 32

Showing results (171-180 of 317) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialEmanuel Bührer, Michal Kicinski, Mario Mandala, et al.
European Urology|June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Melanoma Research|January 3, 2020
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)Elisa A Rozeman, Warner Prevoo, Mark A J Meier, et al.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cardiovascular and Interventional Radiology|January 9, 2023
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin TrialT M L Tong, M C Burgmans, F M Speetjens, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Pageof 32